Regulatory milestones

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $5.67 to $82.90 on Tuesday after reporting $6.5 million in 2Q13 sales of Juxtapid lomitapide for homozygous familial hypercholesterolemia (hoFH), beating the Street's estimate of $4.3 million. On Thursday, the stock added $2.73 to $94.32 after the European Commission approved an MAA for lomitapide as Lojuxta for hoFH.